Home Menu

Site Navigation



ALS News & Research For postings of news or research links and articles related to ALS


advertisement
NeuroTalk Support Groups > > > >

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the

Reply
 
Thread Tools Display Modes
Old 11-02-2016, 08:58 AM #1
MuonOne's Avatar
MuonOne MuonOne is offline
Grand Magnate
  
Join Date: Feb 2007
Posts: 3,271
15 yr Member
MuonOne MuonOne is offline
Grand Magnate
MuonOne's Avatar
 
Join Date: Feb 2007
Posts: 3,271
15 yr Member
Exclamation MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th International Symposium on ALS/MND in Dublin, Ireland

https://globenewswire.com/news-release/2016/10/30/884427/0/en/MediciNova-Announces-MN-166-ibudilast-ALS-Abstract-Accepted-for-Presentation-at-the-27th-International-Symposium-on-ALS-MND-in-Dublin-Ireland.html
MuonOne is offline   Reply With QuoteReply With Quote

advertisement
Old 11-10-2016, 08:52 AM #2
MuonOne's Avatar
MuonOne MuonOne is offline
Grand Magnate
  
Join Date: Feb 2007
Posts: 3,271
15 yr Member
MuonOne MuonOne is offline
Grand Magnate
MuonOne's Avatar
 
Join Date: Feb 2007
Posts: 3,271
15 yr Member
Exclamation Medicinova (MNOV) Receives Positive CHMP Opinion on Ibudilast as ALS Treatment
Medicinova (MNOV) Receives Positive CHMP Opinion on Ibudilast as ALS Treatment

Medicinova (MNOV) Receives Positive CHMP Opinion on Ibudilast as ALS Treatment
MuonOne is offline   Reply With QuoteReply With Quote
Old 11-10-2016, 08:53 AM #3
MuonOne's Avatar
MuonOne MuonOne is offline
Grand Magnate
  
Join Date: Feb 2007
Posts: 3,271
15 yr Member
MuonOne MuonOne is offline
Grand Magnate
MuonOne's Avatar
 
Join Date: Feb 2007
Posts: 3,271
15 yr Member
Exclamation MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product De
MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis

http://www.nasdaq.com/press-release/...20161110-00207
MuonOne is offline   Reply With QuoteReply With Quote
Old 11-16-2016, 12:54 PM #4
MuonOne's Avatar
MuonOne MuonOne is offline
Grand Magnate
  
Join Date: Feb 2007
Posts: 3,271
15 yr Member
MuonOne MuonOne is offline
Grand Magnate
MuonOne's Avatar
 
Join Date: Feb 2007
Posts: 3,271
15 yr Member
Exclamation EU Panel Recommends Orphan Drug Status for Ibudilast for ALS Treatment
EU Panel Recommends Orphan Drug Status for Ibudilast for ALS Treatment

EU Panel Recommends Orphan Drug Status for ALS Therapy Ibudilast
MuonOne is offline   Reply With QuoteReply With Quote
Reply

Tags
abstract, als, medicinova, mn-166, presentation

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Similar Threads
Thread Thread Starter Forum Replies Last Post
MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Am MuonOne ALS News & Research 0 10-12-2016 11:15 AM
NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 In soccertese Parkinson's Disease 4 11-13-2013 10:48 AM
Oxford BioMedica Announces Presentation of New Clinical Data From ProSavin(R) Phase I soccertese Parkinson's Disease 0 05-23-2011 08:02 AM


All times are GMT -5. The time now is 04:43 PM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

All posts copyright their original authors.

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.

Always consult your doctor before trying anything you read here.

Home